Oncology

Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer

Dec 6, 2024

1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with...

Chronic health conditions and employment transition in childhood-cancer survivors

Dec 5, 2024

1. Compared to the general population, survivors of childhood cancer had a greater association...

Nivolumab plus Ipilimumab in MSI-High Metastatic Colorectal Cancer

Dec 3, 2024

1. Progression-free survival at 12 months was 79% with nivolumab/ipilimumab vs 21% with...

Use of certain biologics or disease modifying antirheumatic drugs may be associated with cancer risk

Dec 1, 2024

1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with...

Endometriosis and uterine fibroids associated with a greater risk of mortality due to gynecologic cancers

Nov 30, 2024

1. A history of endometriosis and uterine fibroids in women was associated with a greater risk of...

Fluorouracil, leucovorin and irinotecan plus panitumumab for the treatment of metastatic colorectal cancer

Nov 28, 2024

1. An intermittent strategy with fluorouracil, leucovorin and irinotecan (FOLFIRI) plus...

Early Ramucirumab/Paclitaxel vs Continuation of First-line Chemotherapy in Advanced HER2-negative Gastric/Gastroesophageal Cancer

Nov 26, 2024

1. Median PFS was 6.6 months in the switch maintenance group and 3.5 months in the control group...

Radiotherapy with cetuximab or durvalumab for advanced HNSCC

Nov 19, 2024

1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the...

Refining Fracture Risk Assessment for Patients With Cancer

Nov 15, 2024

FRAX has been validated for fracture risk assessment for patients with cancer, with HRs indicating an association between FRAX scores and fracture risk.

#VisualAbstract: Three Cycles of Chemotherapy was Noninfererior to Six Cycles for High-Risk Retinoblastoma

Nov 12, 2024

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

Nov 12, 2024

1. The median progression-free survival was 15.0 months in the inavolisib and 7.3 months in the...

Emphasizing Societal Benefits of Clinical Trials May Improve Minority Enrollment

Nov 11, 2024

Underscoring how trials can benefit all members of a community and discussing spirituality may improve enrollment of Black patients in cancer clinical trials.